About: COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions
Creator	Ding, Hong Triggle, Chris Bansal, Devendra Sultan, Ali Baker, Elmoubasher Farag, Abd
Source	Medline; PMC
abstract	Coronavirus disease 2019 (COVID-19) is caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first emerged in December 2019 in Wuhan, Hubei province, China. Since then, the virus has rapidly spread to many countries. While the outbreak in China appears to be in decline, the disease has spread across the world, with a daily increase in the number of confirmed cases and infection-related deaths. Here, we highlight (i) the lessons that have been learnt so far and how they will benefit reducing the impact of COVID-19 disease and (ii) an update on the status of drug treatment and vaccine development to prevent COVID-19 and potential future related pandemics. Although the mortality rate is clearly higher than for influenza, the rate does seem to vary from country to country, possibly reflecting differences in how rapidly local health authorities respond to isolate and effectively care for the affected population. Drugs are urgently needed for both prophylaxis and the treatment of severely ill patients; however, no proven effective therapies for SARS-CoV-2 currently exist. A number of drugs that have been approved for other diseases are being tested for the treatment of COVID-19 patients, but there is an absence of data from appropriately designed clinical trials showing that these drugs, either alone or in combination, will prove effective. There is also a global urgency to develop a vaccine against COVID-19, but development and appropriate testing will take at least a year before such a vaccine will be globally available. This review summarizes the lessons learnt so far from the COVID-19 pandemic, examines the evidence regarding the drugs that are being tested for the treatment of COVID19, and describes the progress made in efforts to develop an effective vaccine.
has issue date	2020-05-13(xsd:dateTime)
bibo:doi	10.1128/msphere.00317-20
bibo:pmid	32404514
has license	cc-by
sha1sum (hex)	f19e6dc7dcca05a24443b980926f33ff569abbea
schema:url	https://doi.org/10.1128/msphere.00317-20
resource representing a document's title	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions
has PubMed Central identifier	PMC7227770
has PubMed identifier	32404514
schema:publication	mSphere
resource representing a document's body	covid:f19e6dc7dcca05a24443b980926f33ff569abbea#body_text
is schema:about of	named entity 'effectively' named entity 'virus' named entity 'SARS-CoV-2' named entity 'isolate' named entity 'population' named entity 'Treatment' named entity 'APPROPRIATE' named entity 'DECEMBER' named entity 'BUT' named entity '28I' named entity 'ACROSS' named entity 'PANDEMICS' named entity 'REVIEW' named entity 'LOCAL' named entity 'CORONAVIRUS DISEASE 2019' named entity 'RESPOND TO' named entity 'HIGHER' named entity 'ILL' named entity 'URGENCY' named entity 'OUTBREAK' named entity 'CARE' named entity 'vaccine' named entity 'influenza' named entity 'drug treatment' named entity 'reflecting' named entity 'data' named entity 'combination' named entity 'vaccine' named entity 'China' named entity 'progress' named entity 'develop' named entity 'COVID-19' named entity 'decline' named entity 'impact of COVID-19' named entity 'vaccine against COVID-19' named entity 'mortality rate' named entity 'influenza' named entity 'coronavirus' named entity 'vaccine' named entity 'United States' named entity 'Wuhan' named entity 'control group' named entity 'cardiovascular' named entity 'aerosol' named entity 'Taiwan' named entity 'amino acids' named entity 'half-life' named entity 'Scientific support' named entity 'inhalation' named entity 'proinflammatory cytokines' named entity 'acute respiratory distress syndrome' named entity 'SARS-CoV-2' named entity 'Taiwan' named entity 'China' named entity 'South Korea' named entity 'United States' named entity 'Hubei province' named entity 'Lombardy' named entity 'comorbidities' named entity 'half-life' named entity 'personal protective equipment' named entity 'COVID-19' named entity 'COVID-19' named entity 'Ang II' named entity 'infection' named entity 'receptor' named entity 'spread of COVID-19' named entity 'protein' named entity 'lungs' named entity 'endocytosis' named entity '250,000' named entity 'ACE2' named entity 'COVID' named entity 'hydroxychloroquine' named entity 'Academy of Military Medical Sciences' named entity 'Taiwan'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software